Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 10:27 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 27,833 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Not listed Phase 2Phase 3 Interventional

Modafinil in the Treatment of PTSD (Posttraumatic Stress Disorder)

NCT01726088
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Modafinil
Drug
Lead sponsor
Biomedical Research Foundation
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
North Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Nov 3, 2026, 10:27 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

TDCS to Improve Motivation and Memory in Elderly (TIME)

NCT04268186
View directory record Official record
Conditions
Motivation
Interventions
Direct tDCS, Indirect tDCS, Personalized tDCS, Sham tDCS
Device
Lead sponsor
Northeastern University
Other
Eligibility
65 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Nov 3, 2026, 10:27 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270
View directory record Official record
Conditions
Obesity or Overweight, Diabetes Mellitus, Type 2
Interventions
Lenbelintide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
56
States / cities
Fairhope, Alabama • Huntsville, Alabama • Mobile, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 1 Interventional

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

NCT04201873
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration, Poly ICLC
Biological · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 3, 2026, 10:27 PM EST
Not listed Phase 3 Interventional

Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer

NCT00022373
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Interventions
iseganan HCl oral solution, management of therapy complications
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Nov 3, 2026, 10:27 PM EST
Recruiting Not applicable Interventional

Device for Treating Generalized Anxiety

NCT07819773
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD)
Interventions
EXOMIND (BTL-699-2) Active treatment, EXOMIND (BTL-699-2) Sham treatment
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
22 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Newburgh, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 3, 2026, 10:27 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

NCT07811869
View directory record Official record
Conditions
Chronic Pruritus of Unknown Origin
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Tampa, Florida • Sandy Springs, Georgia • Brighton, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

NCT02852005
View directory record Official record
Conditions
HIV Infections
Interventions
MVA/HIV62B vaccine, AIDSVAX B/E vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Nov 3, 2026, 10:27 PM EST
Not listed Phase 2 Interventional

Alcohol Dependency Study: Combining Medication Treatment for Alcoholism

NCT00006205
View directory record Official record
Conditions
Alcoholism
Interventions
ondansetron + cognitive behavioral therapy, topiramate + cognitive behavioral therapy, Placebo + cognitive behavioral therapy, ondansetron + topiramate + cognitive behavioral therapy
Drug
Lead sponsor
Bankole Johnson
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Nov 3, 2026, 10:27 PM EST
Terminated Not applicable Interventional

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

NCT02548494
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions
Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss
Drug · Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
1 Year to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)

NCT02427529
View directory record Official record
Conditions
HCG
Interventions
Human Chorionic Gonadotropin, Placebo, Low calorie diet
Drug · Other
Lead sponsor
Dr. Emma's Corporation
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Colts Neck, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Nov 3, 2026, 10:27 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains

NCT02855229
View directory record Official record
Conditions
Translational Electrophysiology
Interventions
Methylphenidate
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Nov 3, 2026, 10:27 PM EST
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

NCT06848231
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
YA-101, Placebo
Drug
Lead sponsor
Dasher Neuroscience Inc.
Industry
Eligibility
30 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

NCT00791102
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
ASP-1001 nasal spray, Placebo for ASP-1001
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Days to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 2 Interventional

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

NCT00797953
View directory record Official record
Conditions
Angina Pectoris
Interventions
T89
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 1Phase 2 Interventional Results available

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

NCT03245762
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
1 Week to 6 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242446
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 10:27 PM EST
Completed Not applicable Interventional

Combined Effects of Prunus Cerasus and Apocynum Venetum On Sleep and Anxiety in Adults With Insomnia

NCT06299488
View directory record Official record
Conditions
Insomnia
Interventions
Sip2Sleep: Montmorency Cherry and Apocynum Venetum
Other
Lead sponsor
Lakshmi Nutraceuticals LLC
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 3 Interventional

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

NCT05078827
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
Drug
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 2 Interventional Results available

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

NCT00422461
View directory record Official record
Conditions
Hypertension
Interventions
placebo, PF-00489791
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Los Angeles, California • Santa Ana, California • Tustin, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 3 Interventional Results available

Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method

NCT01986361
View directory record Official record
Conditions
Acute Pharyngitis, Sore Throat
Interventions
flurbiprofen, placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Nov 3, 2026, 10:27 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

NCT04766086
View directory record Official record
Conditions
Group B Streptococcus Infections
Interventions
Multivalent Group B streptococcus vaccine, Tetanus, diphtheria, and acellular pertussis vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
12
States / cities
Newton, Kansas • Omaha, Nebraska • Las Vegas, Nevada + 8 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Nov 3, 2026, 10:27 PM EST
Completed Not applicable Interventional Results available

Effect of TENS for Pain and Function After Total Knee Replacement

NCT01364870
View directory record Official record
Conditions
Unilateral Primary Osteoarthritis of Knee, Primary Osteoarthritis of Knee Nos
Interventions
Placebo TENS, Active TENS
Device
Lead sponsor
Barbara A Rakel
Other
Eligibility
30 Years to 100 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Nov 3, 2026, 10:27 PM EST
Terminated Phase 4 Interventional Results available

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
1,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Nov 3, 2026, 10:27 PM EST